Recently, Cox et al 1 described that only acute lymphoblastic leukemia (ALL) blasts with a CD19 Ϫ CD133 ϩ immune-phenotype are able to propagate human leukemia in immune-deficient nonobese diabetic severe combined immunodeficiency (NOD/scid) mice. We welcome this contribution to the rapidly evolving debate on leukemic stem cells.
groups have detected self-renewing blasts as being restricted to the primitive CD19 Ϫ or CD38 Ϫ stem cell compartment, [1] [2] [3] others found repopulating cells only in the more mature CD19 ϩ lymphoid compartment 4 or within aberrant CD19 ϩ lymphoid cells that lack CD38 expression. 5 To make the picture even more confusing, we have recently shown that a wide variety of blasts at different stages of maturation (CD34 ϩ and CD34 Ϫ , CD19 Ϫ and CD19 ϩ , CD20 Ϫ and CD20 ϩ ) are able to propagate leukemia in natural killer (NK) cell-depleted NOD/scid and NOD/scid gamma (NSG) mice after intrafemoral injection. 6 Unlike the mechanism suggested by Cox et al, 1 our data cannot be explained by prior passage of the human cells in the mice as primary sorted cells show the same engraftment pattern (Table 1) . Although this may have been an obvious concern, we believe that we are not creating in vivo cell lines with an altered stem cell hierarchy.
Similar to our own results, Kong et al 7 have recently shown that both CD34 ϩ CD19 ϩ CD38 Ϫ and CD34 ϩ CD19 ϩ CD38 ϩ blasts in infant ALL/t(4,11) are able to transfer leukemia onto NSG mice.
Most importantly, work out of Civin's laboratory as presented at the 2008 Annual Meeting of the American Society of Hematology showed that, after intravenous injection, as few as 10 unselected ALL cells were sufficient to reinitiate the leukemia in NSG mice. 8 How can it be explained that many groups seem to come up with a different phenotype for ALL stem cells? It is interesting to note that studies identifying rare leukemic stem cells with an immature immune phenotype use more conventional NOD/scid mice as recipients, whereas studies observing leukemia-initiating potential in a wider variety of populations use either NK cell-depleted NOD/scid mice or one of the newer genetically engineered NOD/scid mouse strains with deletion of the IL2 receptor gamma chain (eg, NSG mice). Work from Bonnet's laboratory has elegantly demonstrated that conventional NOD/scid mice can clear human cells coated with certain antibodies, such as anti-CD38. 9 Consequently, these models may not only underestimate the frequency of human stem cells but also wrongly imply a hierarchy between different populations. Similar observations have recently been made in several solid tumor models (reviewed in Dick 10 ): while earlier xenograft assays had suggested the presence of only rare cancer stem cells, recent results using NSG mice showed stem cell frequencies as high as 1 in 4 tumor cells. 
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Much of the confusion could therefore be around methodology. It will be paramount to standardize the xenotransplantation approaches and to use optimized mouse models that offer the least hostile microenvironment for human cells. 10 With these newer and more sensitive models, we may be surprised to find that many more populations have stem cell properties then previously thought. We look forward to continuing this debate. 
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Stem cells in childhood acute lymphoblastic leukemia: identifying the most relevant targets for therapy
We thank Heidenreich and Vormoor for their interest in our paper and we welcome the opportunity to respond. We agree with the authors that this is a very exciting time for research in acute lymphoblastic leukemia (ALL) stem cells and that standardization of methodologies will be paramount for generation of the most clinically relevant data. Indeed, in the discussion of our paper, 1 we postulate that the apparent discrepancies in the published phenotypes of ALL stem cells could be attributed to several variables in the methodologies used. There are differences in the strains of immune-deficient mice used, the inoculation techniques, and in the age of the recipient animals. Kong et al used recipient mice at only 48 hours after birth. 2 Interestingly, the abstract by Morisot et al, to which the authors refer, noted a similar frequency of leukemia stem cells using both nonobese diabetic severe combined immunedeficient (NOD/SCID) gamma (NSG) and the classic NOD/SCID strains, although the onset of leukemia was delayed in the NOD/SCIDs in some cases. 3 It is also important to recognize that different subtypes of leukemia may also contribute to differences in the phenotype of the leukemia initiating cells. Two publications that reported multiple ALL cell phenotypes with leukemia engrafting capacity mainly used samples from high-risk cases. 2, 4 It is interesting to note in the paper by le Viseur 4 and the table included in the letter that fewer CD19 low cells were required to achieve engraftment levels similar to that observed with CD19 high cells in the samples where these phenotypes were compared. Not only will it be crucial to develop xenotransplant models that are profoundly immune deficient to permit identification of any leukemia cells that have stem cell properties, it will also be important to use more sophisticated assays that incorporate cell tracking or transplantation of finite cell numbers to discriminate between leukemia cells with extensive self-renewal ability and those that can proliferate to engraft animal models but have limited self-renewal capacity. Leukemia cells with greater self-renewal ability are likely to be the most relevant to target with novel therapeutic approaches.
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